R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
R-pyocins, bacteriocin-like proteins produced by Pseudomonas aeruginosa, present a promising alternative to phage therapy and/or adjunct to currently used antimicrobials in treating bacterial infections due to their targeted specificity, lack of replication, and stability. This review explores the structural, mechanistic, and therapeutic aspects of R-pyocins, including their potential for chronic infection management, and discusses recent advances in delivery methods, paving the way for novel antimicrobial applications in clinical settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These highly specific agents can target rival strains without damaging the microbiota.”
From Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility (2025) · cites this paper as [165]
In the citing paper
“Finally, pyocins are protein-based bacteriocins produced naturally by P. aeruginosa165.”
From Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility (2025) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms
Turnbull, L., Toyofuku, M., Hynen, A. L., Kurosawa, M., Pessi, G., Petty, N. K., Osvath, S. R., Cárcamo-Oyarce, G., Gloag, E. S., Shimoni, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms11220 · Cited by 709
Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum
Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L., & Whiteley, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419677112 · Cited by 432 · cited 1×
“…transcriptomic data from in vitro sampling in Synthetic Cystic Fibrosis SputumMediawiththewild-typelaboratory P.aeruginosa strainsPA14and PAO1, we fi nd that all samples produced transcripts for the R-pyocin-associated regulatory genes, lytic genes, and structural genes (PA0612-PA0632) 85,86,88 .”
Phage-mediated horizontal gene transfer and its implications for the human gut microbiome
Borodovich, T., Shkoporov, A. N., Ross, R. P., & Hill, C. (2022) · Gastroenterology Report · doi:10.1093/gastro/goac012 · Cited by 200
Immunogenicity of bacteriophages
Champagne-Jorgensen, K., Luong, T., Darby, T., & Roach, D. R. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.04.008 · Cited by 115
Research works printed but not linked: 97
- Hays, E. E. et al. Antibiotic substances produced by Pseudomonas aeruginosa. Biol. Chem. 159, 725–750 (1945). · DOI · Paper page
- Jacob, F. Induced biosynthesis and mode of action of a pyocine, an antibiotic obtained from Ps. pyocyanea. Ann. Inst. Pasteur 86, 149–160 (1954).
- Hugh, R. & Lessel, E. F. Pseudomonas aeruginosa or Pseudomonas pyocyanea? Int. J. Syst. Evol. Microbiol. 17, 43–51 (1967).
- Bradley, D. E. Ultrastructure of bacteriophage and bacteriocins. Bacteriol. Rev. 31, 230–314 (1967). · DOI
- Scholl, D. Phage tail–like bacteriocins. Annu. Rev. Virol. 4, 453–467 (2017). · DOI · Paper page
- Michel-Briand, Y. & Baysse, C. The pyocins of Pseudomonas aeruginosa. Biochimie 84, 499–510 (2002). · DOI · Paper page
- Bradley, D. The structure of pyocin particles released from Pseudomonas aeruginosa by mitomycin C. Int. Congr. Electron Microscopy 6, 115–116 (1966).
- Oluyombo, O., Penfold, C. N. & Diggle, S. P. Competition in biofilms between cystic fibrosis isolates of Pseudomonas aeruginosa is shaped by R-pyocins. mBio 10, e01828–01818 (2019). · DOI
- Kuroda, K. & Kageyama, M. Comparative study of F-type pyocins of Pseudomonas aeruginosa. J. Biochem. 89, 1721–1736 (1981). · doi:10.1093/oxfordjournals.jbchem.a133372
- Ghequire, M. G. et al. O serotype-independent susceptibility of Pseudomonas aeruginosa to lectin-like pyocins. Microbiologyopen 3, 875–884 (2014). · DOI
- Ghequire, M. G. K., Öztürk, B. & De Mot, R. Lectin-like bacteriocins. Front. Microbiol. 9, 2706 (2018). · doi:10.3389/fmicb.2018.02706
- Kuroda, K. & Kagiyama, R. Biochemical relationship among three F-type pyocins, pyocin F1, F2, and F3, and phage KF1. J. Biochem. 94, 1429–1441 (1983). · doi:10.1093/oxfordjournals.jbchem.a134533
- Nakayama, K. et al. The R-type pyocin of Pseudomonas aeruginosa is related to P2 phage, and the F-type is related to lambda phage. Mol. Microbiol. 38, 213–231 (2000). · DOI · Paper page
- Saha, S. et al. F-type pyocins are diverse noncontractile phage tail-like weapons for killing Pseudomonas aeruginosa. J. Bacteriol. 205, e0002923 (2023). · DOI
- Blasco, L. et al. Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents. Sci. Rep. 13, 117 (2023). · DOI
- Sithu Shein, A. M. et al. Phage therapy could be key to conquering persistent bacterial lung infections in children. NPJ Antimicrob. Resist. 2, 31 (2024). · DOI
- Liu, D. et al. The safety and toxicity of phage therapy: a review of animal and clinical studies. J. Viruses 13, 1268 (2021). · DOI · Paper page
- Ikeda, K., Kageyama, M. & Egami, F. Studies of a pyocin II. Mode of production of the pyocin. J. Biochem. 55, 54–58 (1964). · doi:10.1093/oxfordjournals.jbchem.a127840
- Kageyama, M. Studies of a pyocin I. Physical and chemical properties. J. Biochem. 55, 49–53 (1964). · DOI · Paper page
- Ishii, S.-I., Nishi, Y. & Egami, F. The fine structure of a pyocin. J. Mol. Biol. 13, 428–431 (1965). · doi:10.1016/s0022-2836(65)80107-3
- Arias, C. F., Acosta, F. J., Bertocchini, F., Herrero, M. A. & Fernández-Arias, C. The coordination of anti-phage immunity mechanisms in bacterial cells. Nat. Commun. 13, 7412 (2022). · DOI
- Scholl, D. et al. An Engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen Escherichia coli O157:H7. Antimicrob. Agents Chemother. 53, 3074–3080 (2009). · DOI · Paper page
- Alqahtani, A. et al. Recombinant R2-pyocin cream is effective in treating Pseudomonas aeruginosa-infected wounds. Can. J. Microbiol. 67, 919–932 (2021). · doi:10.1139/cjm-2021-0207
- Williams, S. R., Gebhart, D., Martin, D. W. & Scholl, D. Retargeting R-type pyocins to generate novel bactericidal protein complexes. Appl. Environ. Microbiol. 74, 3868–3876 (2008). · DOI · Paper page
- Ohsumi, M., Shinomiya, T. & Kageyama, M. Comparative study on R-type pyocins of Pseudomonas aeruginosa. J. Biochem. 87, 1119–1125 (1980).
- Govan, J. R. W. Studies on the pyocins of Pseudomonas aeruginosa: production of contractile and flexuous pyocins in Pseudomonas aeruginosa. J. Gen. Microbiol. 80, 17–30 (1974). · doi:10.1099/00221287-80-1-17
- Buth, S. A., Shneider, M. M., Scholl, D. & Leiman, P. G. Structure and analysis of R1 and R2 pyocin receptor-binding fibers. J. Viruses 10, 427 (2018). · DOI
- Ge, P. et al. Atomic structures of a bactericidal contractile nanotube in its pre- and postcontraction states. Nat. Struct. Mol. Biol. 22, 377–382 (2015). · DOI · Paper page
- Ge, P. et al. Action of a minimal contractile bactericidal nanomachine. Nature 580, 658–662 (2020). · DOI · Paper page
- Salazar, A. J., Sherekar, M., Tsai, J. & Sacchettini, J. C. R pyocin tail fiber structure reveals a receptor-binding domain with a lectin fold. PLoS ONE 14, e0211432 (2019). · DOI
- Köhler, T., Donner, V. & van Delden, C. Lipopolysaccharide as shield and receptor for R-pyocin-mediated killing in Pseudomonas aeruginosa. J. Bacteriol. 192, 1921–1928 (2010). · DOI · Paper page
- Shinomiya, T. Studies on biosynthesis and morphogenesis of R-type pyocins of Pseudomonas aeruginosa. 3. Subunits of pyocin R and their precipitability by anti-pyocin R serum. J. Biochem. 72, 499–510 (1972). · doi:10.1093/oxfordjournals.jbchem.a129929
- Hardy, J. M., Dunstan, R. A., Lithgow, T. & Coulibaly, F. Tall tails: cryo-electron microscopy of phage tail DNA ejection conduits. Biochem. Soc. Trans. 50, 459–422W (2022). · DOI · Paper page
- Shinomiya, T., Shiga, S. & Kageyama, M. Genetic determinant of pyocin R2 in Pseudomonas aeruginosa PAO. I. Localization of the pyocin R2 gene cluster between the trpCD and trpE genes. Mol. Gen. Genet. 189, 375–381 (1983). · doi:10.1007/bf00325898
- Matsui, H., Sano, Y., Ishihara, H. & Shinomiya, T. Regulation of pyocin genes in Pseudomonas aeruginosa by positive (prtN) and negative (prtR) regulatory genes. J. Bacteriol. 175, 1257–1263 (1993). · doi:10.1128/jb.175.5.1257-1263.1993
- Dorosky, R. J., Pierson, L. S. & Pierson, E. A. Pseudomonas chlororaphis produces multiple R-tailocin particles that broaden the killing spectrum and contribute to persistence in rhizosphere communities. Appl. Environ. Microbiol. 84, e01230–01218 (2018). · DOI
- Ghequire, M. G. K. & De Mot, R. The tailocin tale: peeling off phage tails. Trends Microbiol. 23, 587–590 (2015). · DOI · Paper page
- Ghequire, M. G. K. et al. Different ancestries of R tailocins in rhizospheric Pseudomonas isolates. Genome Biol. Evol. 7, 2810–2828 (2015). · DOI
- Baltrus, D. A., Clark, M., Smith, C. & Hockett, K. L. Localized recombination drives diversification of killing spectra for phage-derived syringacins. ISME J. 13, 237–249 (2019). · DOI
- Kageyama, M. Genetic mapping of pyocin R1 factor in Pseudomonas aeruginosa. J. Gen. Appl. Microbiol. 20, 269–275 (1974). · doi:10.2323/jgam.20.269
- Waite, R. D. & Curtis, M. A. Pseudomonas aeruginosa PAO1 pyocin production affects population dynamics within mixed-culture biofilms. J. Bacteriol. 191, 1349–1354 (2009). · DOI · Paper page
- Penterman, J., Singh, P. K. & Walker, G. C. Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa. J. Bacteriol. 196, 3351–3359 (2014). · DOI · Paper page
- Fernandez, M. et al. Characterization of the bacteriocins and the PrtR regulator in a plant-associated Pseudomonas strain. J. Biotech. 307, 182–192 (2020). · DOI
- Long, Y. et al. Fis Contributes to resistance of Pseudomonas aeruginosa to ciprofloxacin by regulating pyocin synthesis. J. Bacteriol. 202, e00064–00020 (2020). · DOI
- Bronson, A. S., Baggett, N. S. & Cabeen, M. T. DNA damage-inducible pyocin expression is independent of RecA in xerC deleted Pseudomonas aeruginosa. Microbiol. Spectr. 10, e01167–01122 (2022). · doi:10.1128/spectrum.01167-22
- Baggett, N. S., Bronson, A. S. & Cabeen, M. T. SOS-independent pyocin production in P. aeruginosa is induced by XerC recombinase deficiency. mBio 12, e02893–02821 (2021). · DOI
- Penterman, J. et al. Rapid evolution of culture-impaired bacteria during adaptation to biofilm growth. Cell Rep. 6, 293–300 (2014). · DOI
- Vacheron, J., Heiman, C. M. & Keel, C. Live cell dynamics of production, explosive release and killing activity of phage tail-like weapons for Pseudomonas kin exclusion. Commun. Biol. 4, 87 (2021). · DOI
- Hu, B., Margolin, W., Molineux, I. J. & Liu, J. Structural remodeling of bacteriophage T4 and host membranes during infection initiation. Proc. Natl Acad. Sci. USA 112, E4919–E4928 (2015). · DOI
- Govan, J. R. Studies on the pyocins of Pseudomonas aeruginosa: morphology and mode of action of contractile pyocins. J. Gen. Microbiol. 80, 1–15 (1974). · DOI
- Carim, S. et al. Systematic discovery of Pseudomonad genetic factors involved in sensitivity to tailocins. ISME J. 15, 2289–2305 (2021). · DOI · Paper page
- Kandel, P. P., Baltrus, D. A. & Hockett, K. L. Pseudomonas can survive tailocin killing via persistence-like and heterogenous resistance mechanisms. J. Bacteriol. 202, e00142-20 (2020). · DOI
- Ikeda, K. & Egami, F. Lipopolysaccharide of Pseudomonas aeruginosa with special reference to pyocin R receptor activity. J. Gen. Appl. Microbiol. 19, 115–128 (1973). · doi:10.2323/jgam.19.115
- Kocíncová, D. & Lam, J. S. A deletion in the wapB promoter in many serotypes of Pseudomonas aeruginosa accounts for the lack of a terminal glucose residue in the core oligosaccharide and resistance to killing by R3-pyocin. Mol. Microbiol. 89, 464–478 (2013). · DOI
- Uratani, Y. & Hoshino, T. Pyocin R1 inhibits active transport in Pseudomonas aeruginosa and depolarizes membrane potential. J. Bacteriol. 157, 632–636 (1984). · DOI
- Maldonado, R. F., Sá-Correia, I. & Valvano, M. A. Lipopolysaccharide modification in Gram-negative bacteria during chronic infection. FEMS Microbiol. Rev. 40, 480–493 (2016). · DOI · Paper page
- Faure, E., Kwong, K. & Nguyen, D. Pseudomonas aeruginosa in chronic lung infections: how to adapt within the host? Front. Immunol. 9, 2416 (2018). · DOI · Paper page
- Faure, K. et al. O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa. J. Clin. Microbiol. 41, 2158–2160 (2003). · DOI
- Diggle, S. P & Whiteley, M. Microbe profile: Pseudomonas aeruginosa: opportunistic pathogen and lab rat. Microbiology 166, 30–33 (2020). · DOI · Paper page
- Aswathanarayan, J. B., Rao, P., Siddaiahswamy, H. M., Sowmya, G. S. & Rai, R. V. Advances in Microbiology, Infectious Diseases and Public Health, Vol. 17 (ed. Donelli, G.) 55–75 (Springer, 2023). · DOI
- Turner, K. H., Everett, J., Trivedi, U., Rumbaugh, K. P. & Whiteley, M. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 10, e1004518 (2014). · DOI · Paper page
- Spencer, D. H. et al. Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J. Bacteriol. 185, 1316–1325 (2003). · DOI · Paper page
- Sandiumenge, A. et al. Impact of diversity of antibiotic use on the development of antimicrobial resistance. J. Antimicrob. Chemother. 57, 1197–1204 (2006). · DOI
- Hogardt, M. & Heesemann, J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300, 557–562 (2010). · DOI · Paper page
- Mowat, E. et al. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 183, 1674–1679 (2011). · DOI · Paper page
- Chung, J. C. S. et al. Genomic variation among contemporary Pseudomonas aeruginosa isolates from chronically infected cystic fibrosis patients. J. Bacteriol. 194, 4857 (2012). · DOI
- Workentine, M. et al. Phenotypic Heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 8, e60225 (2013). · DOI · Paper page
- Winstanley, C., O’Brien, S. & Brockhurst, M. A. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 24, 327–337 (2016). · DOI · Paper page
- Acosta, N. et al. Cystic fibrosis patients infected with epidemic Pseudomonas aeruginosa strains have unique microbial communities. Front. Cell. Infect. Microbiol. 10, 173 (2020). · DOI
- Azimi, S. et al. Allelic polymorphism shapes community function in evolving Pseudomonas aeruginosa populations. ISME J 14, 1929–1942 (2020). · DOI · Paper page
- Vanderwoude, J., Azimi, S., Read Timothy, D. & Diggle Stephen, P. The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of Pseudomonas aeruginosa populations in cystic fibrosis lung infection. mBio 15, e03109–e03123 (2024). · DOI
- Sousa, A. M. & Pereira, M. O. Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs—a review. J. Pathog. 3, 680–703 (2014). · DOI · Paper page
- Mei, M., Pheng, P., Kurzeja-Edwards, D. & Diggle, S. P. High prevalence of lipopolysaccharide mutants and R2-pyocin susceptible variants in Pseudomonas aeruginosa populations sourced from cystic fibrosis lung infections. Microbiol. Spectr. 11, e01773–01723 (2023). · DOI
- Mei, M., Thomas, J. & Diggle, S. P. Heterogenous susceptibility to R-pyocins in populations of Pseudomonas aeruginosa sourced from cystic fibrosis lungs. mBio 12, e00458–00421 (2021). · DOI
- Redero, M. et al. Susceptibility to R-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients. J. Antimicrob. Chemother. 73, 2770–2776 (2018). · doi:10.1093/jac/dky261
- Bara, J. J., Matson, Z. & Remold, S. K. Life in the cystic fibrosis upper respiratory tract influences competitive ability of the opportunistic pathogen Pseudomonas aeruginosa. R. Soc. Open Sci. 5, 180623 (2018). · DOI
- Redero, M., Aznar, J. & Prieto, A. I. Antibacterial efficacy of R-type pyocins against Pseudomonas aeruginosa on biofilms and in a murine model of acute lung infection. J. Antimicrob. Chemother. https://doi.org/10.1093/jac/dkaa121 (2020). · DOI
- Oliver, A., Mulet, X., López-Causapé, C. & Juan, C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist. Updat. 21-22, 41–59 (2015). · DOI · Paper page
- Rada, A. M. et al. Genetic diversity of multidrug-resistant Pseudomonas aeruginosa isolates carrying blaVIM–2 and blaKPC–2 genes that spread on different genetic environment in Colombia. Front. Microbiol. 12, 663020 (2021). · DOI
- del Barrio-Tofiño, E., López-Causapé, C. & Oliver, A. Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update. Int. J. Antimicrob. Agents 56, 106196 (2020). · DOI · Paper page
- Cornforth, D. M. et al. Pseudomonas aeruginosa transcriptome during human infection. Proc. Natl Acad. Sci. USA 115, E5125–E5134 (2018). · DOI · Paper page
- Cornforth, D. M., Diggle, F. L., Melvin, J. A., Bomberger, J. M. & Whiteley, M. Quantitative framework for model evaluation in microbiology research using Pseudomonas aeruginosa and cystic fibrosis infection as a test case. mBio 11, e03042-19 (2020). · DOI · Paper page
- Wu, X. et al. in vivo proteome of Pseudomonas aeruginosa in airways of cystic fibrosis patients. J. Proteome Res. 18, 2601–2612 (2019). · DOI
- Scholl, D. & Martin, D. W. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob. Agents Chemother. 52, 1647–1652 (2008). · doi:10.1128/aac.01479-07
- Berkson, J. D. et al. Phage-specific immunity impairs efficacy of bacteriophage targeting vancomycin resistant Enterococcus in a murine model. Nat. Commun. 15, 2993 (2024). · DOI
- Łusiak-Szelachowska, M. et al. Do anti-phage antibodies persist after phage therapy? A preliminary report. J. Antibiot. 11, 1358 (2022). · DOI
- Bernabéu-Gimeno, M. et al. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 5, 1096–1111.e1096 (2024). · DOI
- Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019). · DOI · Paper page
- Christiane, E. et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8, e60575 (2013). · DOI
- Forti, F. et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob. Agents Chemother. 62, e02573-17 (2018). · DOI · Paper page
- Shafigh Kheljan, F. et al. Design of phage-cocktail-containing hydrogel for the treatment of Pseudomonas aeruginosa-infected wounds. J. Viruses 15, 803 (2023). · DOI
- Agarwal, R. et al. Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections. Nat. Biomed. Eng. 2, 841–849 (2018). · DOI · Paper page
- Morse, S. A., Vaughan, P., Johnson, D. & Iglewski, B. H. Inhibition of Neisseria gonorrhoeae by a bacteriocin from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 10, 354–362 (1976). · doi:10.1128/aac.10.2.354
- Blackwell, C. C., Young, H. & Anderson, I. Sensitivity of Neisseria gonorrhoeae to partially purified R-type pyocines and a possible approach to epidemiological typing. J. Med. Microbiol. 12, 321–335 (1979). · doi:10.1099/00222615-12-3-321
- Campagnari, A. A. et al. Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis. Infect. Immun. 62, 2379–2386 (1994). · doi:10.1128/iai.62.6.2379-2386.1994
- Rotman, E. et al. Rapid design of bacteriophage cocktails to suppress the burden and virulence of gut-resident carbapenem-resistant Klebsiella pneumoniae. Cell Host Microbe 32, 1988–2003.e1988 (2024). · DOI
- Hoyle, N. et al. Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report. Res. Microbiol. 169, 540–542 (2018). · DOI
Cited by
Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility
Letizia, M., Diggle, S. P., & Whiteley, M. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01193-8 · Cited by 231
Self-citation
Metadata
- Authors
- Mei, M., Estrada, I., Diggle, S. P., & Goldberg, J. B.
- Venue
- npj Antimicrobials and Resistance
- Published
- 2025-02-28
- Volume
- 3
- Issue
- 1
- ISSN
- 2731-8745
- Cited by
- 20
- References
- 5
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Funders
- National Institutes of Health (R21 AI17802; R01AI153116; T32AI074492)
- Cystic Fibrosis Foundation (GOLDBE23G0; DIGGLE18I0; DIGGLE20G0)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1038/s44259-025-00088-1
- The paper
- Mei, M., Estrada, I., Diggle, S. P., & Goldberg, J. B. (2025). R-pyocins as targeted antimicrobials against Pseudomonas aeruginosa. npj Antimicrobials and Resistance. https://doi.org/10.1038/s44259-025-00088-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.